Susan is Vice President of Process Development at bluebird bio in Cambridge, MA. There she leads teams developing processes and analytical methods for lentiviral vector and cellular drug product manufacturing to deliver bluebird bio’s pipeline of autologous cell-based gene therapies. Prior to joining bluebird, Susan spent more than ten years developing and characterizing biologics drug substance processes and supporting commercial manufacturing at Bristol-Myers Squibb (BMS) at the Devens, MA and Syracuse, NY sites. She held various positions in Biologics Development and Operations during her tenure and supported biologics drug substance manufacturing processes across the BMS network. As a CMC leader at BMS, Susan contributed to the successful clinical and commercial manufacturing of several Fc fusion proteins and monoclonal antibodies, including the launches of Yervoy®, Nulojix®, Empliciti™ and Opdivo®. She was among the first to demonstrate the application of QbD to mammalian cell culture processes. Prior to joining BMS, Susan was a member of the process development organization at Bayer Healthcare in Berkeley, CA, utilizing perfusion cell culture for the manufacture of recombinant Factor VIII.